Q2 2025 EPS Estimates for Haemonetics Co. (NYSE:HAE) Cut by Analyst

Haemonetics Co. (NYSE:HAE) – Stock analysts at Zacks Research dropped their Q2 2025 earnings per share estimates for shares of Haemonetics in a research note issued on Monday, October 7th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $1.09 per share for the quarter, down from their previous estimate of $1.10. The consensus estimate for Haemonetics’ current full-year earnings is $4.57 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2026 earnings at $1.28 EPS and FY2026 earnings at $5.15 EPS.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The business had revenue of $336.17 million during the quarter, compared to analysts’ expectations of $335.08 million. During the same quarter in the previous year, the firm earned $1.05 earnings per share. Haemonetics’s revenue was up 8.0% on a year-over-year basis.

A number of other research firms also recently commented on HAE. CL King began coverage on shares of Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 target price on the stock. Barrington Research reaffirmed an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a report on Monday, September 23rd. Citigroup decreased their target price on Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a report on Thursday, August 22nd. Bank of America initiated coverage on Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price target on the stock. Finally, Needham & Company LLC upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a research report on Wednesday, June 12th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $106.14.

Haemonetics Stock Down 0.7 %

NYSE:HAE opened at $76.68 on Wednesday. The company has a market cap of $3.91 billion, a price-to-earnings ratio of 33.48, a price-to-earnings-growth ratio of 1.19 and a beta of 0.30. The company has a current ratio of 3.76, a quick ratio of 2.33 and a debt-to-equity ratio of 1.35. Haemonetics has a twelve month low of $70.74 and a twelve month high of $97.97. The stock has a fifty day simple moving average of $77.47 and a 200-day simple moving average of $84.06.

Insider Activity

In other news, insider Stewart W. Strong sold 4,312 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the sale, the insider now directly owns 18,196 shares of the company’s stock, valued at approximately $1,658,565.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Anila Lingamneni sold 2,136 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total value of $192,240.00. Following the sale, the executive vice president now owns 21,410 shares of the company’s stock, valued at approximately $1,926,900. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stewart W. Strong sold 4,312 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the transaction, the insider now owns 18,196 shares in the company, valued at approximately $1,658,565.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Haemonetics

Several hedge funds have recently modified their holdings of the stock. Dynamic Advisor Solutions LLC boosted its holdings in Haemonetics by 10.1% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 20,154 shares of the medical instruments supplier’s stock worth $1,620,000 after acquiring an additional 1,848 shares during the period. Handelsbanken Fonder AB boosted its holdings in Haemonetics by 23.9% in the third quarter. Handelsbanken Fonder AB now owns 17,095 shares of the medical instruments supplier’s stock worth $1,374,000 after purchasing an additional 3,300 shares during the period. Central Pacific Bank Trust Division grew its position in shares of Haemonetics by 31.1% during the 3rd quarter. Central Pacific Bank Trust Division now owns 2,765 shares of the medical instruments supplier’s stock valued at $222,000 after buying an additional 656 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Haemonetics during the 2nd quarter worth approximately $140,000. Finally, Point72 Asset Management L.P. increased its position in Haemonetics by 178.3% in the second quarter. Point72 Asset Management L.P. now owns 219,024 shares of the medical instruments supplier’s stock worth $18,120,000 after buying an additional 140,324 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.